

CELGENE CORP /DE/  
Form 425  
January 07, 2019

Filed by Bristol-Myers Squibb Company  
Pursuant to Rule 425 of the Securities Act of 1933  
and deemed filed pursuant to Rule 14a-12  
of the Securities Exchange Act of 1934  
Subject Company: Celgene Corporation  
Commission File No.: 001-34912

Explanatory Note: The following slides were used by Bristol-Myers Squibb Company and Celgene Corporation at the JP Morgan Healthcare Conference on January 7, 2019.

Filed by Bristol-Myers Squibb Company Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Celgene Corporation Commission File No.: 001-34912 Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at the JP Morgan Healthcare Conference.

---



This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), Bristol-Myers Squibb and Celgene will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a Bristol-Myers Squibb registration statement on Form S-4 that will include a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb, and a definitive joint proxy statement/prospectus will be mailed to stockholders of Bristol-Myers Squibb and Celgene. **INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.** Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at <http://www.sec.gov>. Copies of the documents filed with the SEC by Bristol-Myers Squibb will be available free of charge on Bristol-Myers Squibb’s internet website at <https://www.bms.com/> under the tab, “Investors” and under the heading “Financial Reporting” and subheading “SEC Filings” or by contacting Bristol-Myers Squibb’s Investor Relations Department through <https://www.bms.com/investors/investor-contacts.html>. Copies of the documents filed with the SEC by Celgene will be available free of charge on Celgene’s internet website at <https://www.celgene.com/> under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at [ir@celgene.com](mailto:ir@celgene.com). Certain Information Regarding Participants Bristol-Myers Squibb, Celgene, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Bristol-Myers Squibb is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 13, 2018, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on March 22, 2018, and its Current Report on Form 8-K, which was filed with the SEC on August 28, 2018. Information about the directors and executive officers of Celgene is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 7, 2018, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on April 30, 2018, and its Current Reports on Form 8-K, which were filed with the SEC on June 1, 2018, June 19, 2018 and November 2, 2018. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at <http://www.sec.gov> and from Investor Relations at Bristol-Myers Squibb or Celgene as described above. **Important Information for Investors and Stockholders**

---



be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the proposed acquisition; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene's businesses; management's time and attention is diverted on transaction-related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company declines following the proposed acquisition; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb's and Celgene's operating results. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Bristol-Myers Squibb or Celgene. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Bristol-Myers Squibb or Celgene, Bristol-Myers Squibb's ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. You are cautioned not to rely on Bristol-Myers Squibb's and Celgene's forward-looking statements. These forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither Bristol-Myers Squibb nor Celgene assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. Cautionary Statement Regarding Forward Looking Statements

---

Creating a Leading Focused Biopharma Company ONCOLOGY: IO / SOLID TUMORS & HEMATOLOGY CARDIOVASCULAR 10 PHASE III ASSETS LEADING FRANCHISES Led by Opdivo and Yervoy as well as Revlimid and Pomalyst ROBUST EARLY-STAGE PIPELINE (PHASE I / II ASSETS) 21 ONCOLOGY: IO / Solid Tumors DEEP AND BROAD LATE-STAGE PIPELINE 20+ LIFE CYCLE MANAGEMENT OPPORTUNITIES IN IO 6 NEAR-TERM POTENTIAL NEW PRODUCT LAUNCHES 10 ONCOLOGY: Hematology CHEMISTRY BIOLOGICS CELL THERAPY Underpinned by cutting edge technologies and discovery platforms 10 IMMUNOLOGY & INFLAMMATION 9 CARDIOVASCULAR/ FIBROSIS Led by Eliquis #1 With access to additional modality platforms through strong external partnerships PATIENT-CENTRIC INNOVATION Led by Orencia and Otezla Top 5 IMMUNOLOGY & INFLAMMATION #1

---

Key Value Drivers Marketed Products & Cashflow Cost Synergies Potential Near-Term Product Launches Early Pipeline & Platforms Cashflows to facilitate de-leveraging Leading commercial hematology platform \$2.5B run-rate expected by year 3 Efficiencies across SG&A, R&D and Manufacturing Luspatercept Ozanimod Liso-cel (JCAR017) bb2121 Fedratinib Nearly doubles early stage pipeline Cell Therapy BCMATechnology Platforms

---

Creating a Leading Focused Biopharma Company ONCOLOGY: IO / SOLID TUMORS & HEMATOLOGY CARDIOVASCULAR 10 PHASE III ASSETS LEADING FRANCHISES Led by Opdivo and Yervoy as well as Revlimid and Pomalyst ROBUST EARLY-STAGE PIPELINE (PHASE I / II ASSETS) 21 ONCOLOGY: IO / Solid Tumors DEEP AND BROAD LATE-STAGE PIPELINE 20+ LIFE CYCLE MANAGEMENT OPPORTUNITIES IN IO 6 NEAR-TERM POTENTIAL NEW PRODUCT LAUNCHES 10 ONCOLOGY: Hematology CHEMISTRY BIOLOGICS CELL THERAPY Underpinned by cutting edge technologies and discovery platforms 10 IMMUNOLOGY & INFLAMMATION 9 CARDIOVASCULAR/ FIBROSIS Led by Eliquis #1 With access to additional modality platforms through strong external partnerships PATIENT-CENTRIC INNOVATION Led by Orencia and Otezla Top 5 IMMUNOLOGY & INFLAMMATION #1

---